Prominent publications by Daniel R Kuritzkes

KOL Index score: 15602

BACKGROUND: Nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy is not suitable for all treatment-naive HIV-infected persons.

OBJECTIVE: To evaluate 3 nonnucleoside reverse transcriptase inhibitor-sparing initial antiretroviral regimens to show equivalence for virologic efficacy and tolerability.

DESIGN: A phase 3, open-label study randomized in a 1:1:1 ratio with follow-up for at least 96 weeks. ( NCT00811954).

SETTING: 57 sites in the United ...

Also Ranks for: Reverse Transcriptase |  antiretroviral regimens |  virologic failure |  protease inhibitors |  ritonavirboosted darunavir
KOL Index score: 15069

BACKGROUND: The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor.

METHODS: Patients from 48 sites in the United States, Canada, Mexico, and Brazil with at least six months of previous treatment with agents in three classes of antiretroviral drugs, resistance to drugs in these classes, or both, and with at least 5000 copies of HIV-1 RNA per milliliter of plasma ...

Also Ranks for: Hiv1 Rna |  enfuvirtide control |  cubic millimeter |  24 weeks |  resistant hiv
KOL Index score: 15025

BACKGROUND: Blacks had higher rates of virologic failure than whites on efavirenz-containing regimens in the AIDS Clinical Trials Group (ACTG) A5095 study; preliminary analyses also suggested an association with adherence. We rigorously examined associations over time among race, virologic failure, 4 self-reported adherence metrics, and quality of life (QOL).

METHODS: ACTG A5095 was a double-blind placebo-controlled study of treatment-naive HIV-positive patients randomized to ...

Also Ranks for: Virologic Failure |  racial differences |  life qol |  hiv therapy |  zidovudine lamivudine
KOL Index score: 14910

Nonnucleoside reverse transcriptase (RT) inhibitors (NNRTI) and integrase (IN) strand transfer inhibitors (INSTI) are key components of antiretroviral regimens. To explore potential interactions between NNRTI and INSTI resistance mutations, we investigated the combined effects of these mutations on drug susceptibility and fitness of human immunodeficiency virus type 1 (HIV-1). In the absence of drug, single-mutant viruses were less fit than the wild type; viruses carrying multiple ...

Also Ranks for: Viral Fitness |  reverse transcriptase |  drug susceptibility |  integrase strand |  resistance mutations
KOL Index score: 14820

Resistance to enfuvirtide (ENF; T-20), a fusion inhibitor of human immunodeficiency virus type 1 (HIV-1), is conferred by mutations in the first heptad repeat of the gp41 ectodomain. The replicative fitness of recombinant viruses carrying ENF resistance mutations was studied in growth competition assays. ENF resistance mutations, selected in vitro or in vivo, were introduced into the env gene of HIV-1(NL4-3) by site-directed mutagenesis and expressed in HIV-1 recombinants carrying ...

Also Ranks for: Virus Type |  replicative fitness |  human immunodeficiency |  enf resistance mutations |  1 mutants
KOL Index score: 14708

BACKGROUND: It is unknown if extremely early initiation of antiretroviral therapy (ART) may lead to long-term ART-free HIV remission or cure. As a result, we studied 2 individuals recruited from a pre-exposure prophylaxis (PrEP) program who started prophylactic ART an estimated 10 days (Participant A; 54-year-old male) and 12 days (Participant B; 31-year-old male) after infection with peak plasma HIV RNA of 220 copies/mL and 3,343 copies/mL, respectively. Extensive testing of blood and ...

Also Ranks for: Hiv1 Rna Art |  acute hiv |  cd4 cells |  early initiation |  antiretroviral therapy
KOL Index score: 14184

BACKGROUND: The reverse-transcriptase inhibitor lamivudine has in vitro synergy with zidovudine against the human immunodeficiency virus (HIV). We studied the activity and safety of lamivudine plus zidovudine as compared with either drug alone as treatment for patients with HIV infection, most of whom had not previously received zidovudine.

METHODS: Three hundred sixty-six patients with 200 to 500 CD4+ cells per cubic millimeter who had received zidovudine for four weeks or less were ...

Also Ranks for: Lamivudine Zidovudine |  cubic millimeter |  combination therapy |  cd4 cells |  hiv1 rna
KOL Index score: 14179

OBJECTIVE: To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination therapy in antiretroviral-naive patients.

DESIGN: Phase IIb, single-arm, open-label, multicenter study.

METHODS: One hundred and twelve antiretroviral-naive, HIV-1-infected patients received DRV/r 800/100 mg once daily and RAL 400 mg twice daily. Primary endpoint was virologic failure by week 24. Virologic failure was defined as confirmed viral load of 1000 copies/ml or more at week 12, or an increase of ...

Also Ranks for: Virologic Failure |  viral load |  100000 copies |  infected patients |  hiv1 humans
KOL Index score: 14017

OBJECTIVE: Assays for drug resistance testing in human immunodeficiency virus type 1 (HIV-1) infection are now available and clinical studies suggest that viral drug resistance is correlated with poor virologic response to new therapy. The International AIDS Society-USA sought to update prior recommendations to provide guidance for clinicians regarding indications for HIV-1 resistance testing.

PARTICIPANTS: An International AIDS Society-USA 13-member physician panel with expertise in ...

Also Ranks for: Viral Drug Resistance |  usa panel |  infectious rna |  microbial drug therapy |  aids society
KOL Index score: 13848

CONTEXT: Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen.

OBJECTIVE: To compare the safety/efficacy of 3-drug vs 4-drug regimens for initial treatment of HIV-1 infection.

DESIGN: The AIDS Clinical Trials Group (ACTG) A5095 study, a randomized, double-blind, placebo-controlled study with enrollment and ...

Also Ranks for: Initial Treatment |  antiretroviral regimens |  hiv1 infection |  zidovudine lamivudine |  randomized controlled trial
KOL Index score: 13571

BACKGROUND: An effective therapeutic vaccine that could augment immune control of HIV-1 replication may abrogate or delay the need for antiretroviral therapy. AIDS Clinical Trials Group (ACTG) A5187 was a phase I/II, randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of an HIV-1 DNA vaccine (VRC-HVDNA 009-00-VP) in subjects treated with antiretroviral therapy during acute/early HIV-1 infection. ( NCT00125099)

METHODS: Twenty ...

Also Ranks for: Antiretroviral Therapy |  safety immunogenicity |  dna vaccination |  treatment discontinuation |  hiv1 infection
KOL Index score: 12556

BACKGROUND: Regimens containing three nucleoside reverse-transcriptase inhibitors offer an alternative to regimens containing nonnucleoside reverse-transcriptase inhibitors or protease inhibitors for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection, but data from direct comparisons are limited.

METHODS: This randomized, double-blind study involved three antiretroviral regimens for the initial treatment of subjects infected with HIV-1: ...

Also Ranks for: Initial Treatment |  nucleoside regimens |  hiv1 infection |  zidovudine lamivudine |  viral drug therapy
KOL Index score: 12498

BACKGROUND: Emergence of human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of antiretroviral therapy in resource-limited settings. The prevalence of resistance was assessed among patients from KwaZulu Natal, South Africa, following failure of their first highly active antiretroviral therapy (HAART) regimen.

METHODS: Genotypic resistance testing was performed on plasma virus samples from patients who experienced virologic failure of their first HAART ...

Also Ranks for: South Africa |  kwazulu natal |  antiretroviral therapy |  highly active |  missense rna

Key People For Antiretroviral Therapy

Top KOLs in the world
Andrew * *********
antiretroviral therapy viral load hiv infection
Jens ******* ********
antiretroviral therapy hiv infection viral load
Peter ******
antiretroviral therapy hiv infection myocardial infarction
David * ******
antiretroviral therapy hiv infection viral load
Joseph * ****
antiretroviral therapy united states hiv infection
Douglas * ********
antiretroviral therapy hiv infection human immunodeficiency virus

Daniel R Kuritzkes:Expert Impact

Concepts for whichDaniel R Kuritzkeshas direct influence:Antiretroviral therapy,  Virologic failure,  South africa,  Resistance mutations,  Reverse transcriptase,  Viral load,  Hiv infection,  Human immunodeficiency virus.

Daniel R Kuritzkes:KOL impact

Concepts related to the work of other authors for whichfor which Daniel R Kuritzkes has influence:Antiretroviral therapy,  Hiv infection,  Viral load,  Reverse transcriptase,  Human immunodeficiency virus,  Resistance mutations,  Protease inhibitors.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA | Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA | Division of Infectious Diseases, Brigham and Women's Hospital,